Larimar Therapeutics, Inc. Profile Avatar - Palmy Investing

Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical tria…

Biotechnology
US, Bala Cynwyd [HQ]
Supply · Problems · Premarket · Compliance

Supply Analysis

End of LRMR's Analysis
CIK: 1374690 CUSIP: 517125100 ISIN: US5171251003 LEI: - UEI: -
Secondary Listings
LRMR has no secondary listings inside our databases.